Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general
population and increases further in cancer patients. The risk of VTE is higher in multiple …

Background Since 1960, oral melphalan and prednisone (MP) has been regarded as the
standard of care in elderly multiple myeloma patients. This multicentre randomised trial …

Remarkable advances in nano delivery systems have provided new hope for tumor
prevention, diagnosis and treatment. However, only limited clinical therapeutic effects …

Thalidomide, bortezomib, and lenalidomide have recently changed the treatment paradigm
of myeloma. In young, newly diagnosed patients, the combination of thalidomide and …

Patients with hematologic malignancies are at high risk of thrombotic or hemorrhagic
complications. The incidence of these events is greatly variable and is influenced by many …

The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but
not yet demonstrated in a randomised‐controlled trial. A systematic review of the published …

Introduction: The incidence of venous thromboembolism (VTE) in patients with multiple
myeloma (MM) treated with thalidomide‐and lenalidomide‐based regimens is high. Recent …

Nanotechnology has enabled the development of novel therapeutic and diagnostic
strategies, such as advances in targeted drug delivery systems, versatile molecular imaging …

Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly
17,000 individuals and kills more than 11,000. Although no cure exists, many effective …